




RealRate

PHARMACEUTICAL 2022

Gemini Therapeutics Inc. DE
Rank 305 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of Gemini Therapeutics Inc. DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Gemini Therapeutics Inc. DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 174% points. The greatest weakness of Gemini Therapeutics Inc. DE is the variable Net Income, reducing the Economic Capital Ratio by 148% points.

The company's Economic Capital Ratio, given in the ranking table, is -198%, being 78% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	140,100
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,834
Liabilities, Non-Current	0
Other Assets	337
Other Compr. Net Income	0
Other Expenses	2,869
Other Liabilities	762
Other Net Income	2.0
Property and Equipment	0
Research and Development	48,717
Revenues	0
Selling, General and Administrative Expense	20,285

Output Variable	Value in 1000 USD
Assets	140,437
Liabilities	15,596
Expenses	71,871
Stockholders Equity	124,841
Net Income	-71,869
Comprehensive Net Income	-71,869
Economic Capital Ratio	-198%